Life Sciences

GSK adopts Chai Discovery AI models

GSK signed up to use Chai Discovery’s protein-folding and design models after wet-lab validation, joining several other major pharmaceutical customers.

GSK joined Chai Discovery’s group of pharmaceutical customers to access the company’s protein-folding and protein-design models. The source says Chai has also established agreements with Bristol Myers Squibb, Eli Lilly, Novartis, and Pfizer, and raised a $400 million Series C round. The collaboration reflects growing pharmaceutical interest in AI systems that model and design proteins for drug discovery. It also indicates that large drug companies are seeking access to specialized external models rather than relying exclusively on internally developed tools. The available article does not provide details about GSK’s specific programs, target proteins, validation results, or commercial terms.

Original source: Fierce Biotech

Related RAQI solutions

In-depth analysis on RAQI Insight

Work with RAQI